Test Discovered for Earlier Detection of Transplant Rejection
|
By LabMedica International staff writers Posted on 06 Apr 2017 |

Image: The NanoSight NS300 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
A method has been discovered that appears to provide earlier warning of organ transplant rejection compared to standard methods, and requires only a blood test rather than a more invasive and painful needle biopsy.
Approximately 30,000 organ transplants occur in the USA each year. However, depending on the organ type of the transplanted organs, between 20% and 50% fail within five years, most often because the recipient's immune system attacks, or "rejects," the donated organ.
Scientists at the Perelman School of Medicine at the University of Pennsylvania analyzed human blood and urine samples using a new method. The new method involves tiny, capsule-like structures known as exosomes, which normally are secreted from most types of cell. Precisely what exosomes evolved to do is not clear, but scientists know that these capsules contain proteins and other molecules from their mother cell that can influence the activities of neighboring cells. Like their mother cells, exosomes have protein markers on their surfaces, often called major histocompatibility complex (MHC) antigens that identify them to the immune system as part of the body. Just as donor and host cells usually differ in their MHC markers, so do donor and host exosomes.
Human pancreas was processed for islet isolation, and high-purity (>80%) islets were used for xenoislet transplantation. Islet isolation was performed and the islets were cultured in CMRL media supplemented with albumin, without any exogenous exosome contamination. Islet culture supernatant (20 mL) was obtained 24 to72 hours after isolation for exosome analysis. Exosomes were isolated from human islet culture supernatants by size exclusion limit gel chromatography along with ultracentrifugation. Exosomes were analyzed on the NanoSight NS300 (405 nm laser diode) on the light scatter mode for quantification and scatter distribution.
In an initial exploration of the transplant-exosome strategy in people, the team examined stored blood plasma samples from five recipients of transplanted islet cells in a clinical trial, and was able to detect donor exosomes in these samples following the transplants. They also found some preliminary evidence that their falling-exosome measure could be useful in predicting transplant rejection in people. For one patient who experienced a rejection of the transplanted islet cells, a steep drop in the level of donor exosomes was detectable in a blood sample taken six and a half months before the transplanted cells stopped working and the patient developed clinical signs of diabetes.
The scientists showed that they could isolate and detect donor-tissue exosomes in a different type of transplant: kidney transplant, currently the most common type of organ transplant. In this case, the team found that they could isolate and quantify donor-kidney exosomes not just in blood but also in urine, thus potentially enabling urine tests which are even less invasive than blood tests. Ali Naji, MD, PhD, a Professor of Surgery and senior author of the study said, “I believe that analyses of exosomes from transplanted organs will ultimately provide a very powerful and unprecedented ability to understand the conditional state of the organ as a whole.” The study was published on March 20, 2017, in the Journal of Clinical Investigation.
Approximately 30,000 organ transplants occur in the USA each year. However, depending on the organ type of the transplanted organs, between 20% and 50% fail within five years, most often because the recipient's immune system attacks, or "rejects," the donated organ.
Scientists at the Perelman School of Medicine at the University of Pennsylvania analyzed human blood and urine samples using a new method. The new method involves tiny, capsule-like structures known as exosomes, which normally are secreted from most types of cell. Precisely what exosomes evolved to do is not clear, but scientists know that these capsules contain proteins and other molecules from their mother cell that can influence the activities of neighboring cells. Like their mother cells, exosomes have protein markers on their surfaces, often called major histocompatibility complex (MHC) antigens that identify them to the immune system as part of the body. Just as donor and host cells usually differ in their MHC markers, so do donor and host exosomes.
Human pancreas was processed for islet isolation, and high-purity (>80%) islets were used for xenoislet transplantation. Islet isolation was performed and the islets were cultured in CMRL media supplemented with albumin, without any exogenous exosome contamination. Islet culture supernatant (20 mL) was obtained 24 to72 hours after isolation for exosome analysis. Exosomes were isolated from human islet culture supernatants by size exclusion limit gel chromatography along with ultracentrifugation. Exosomes were analyzed on the NanoSight NS300 (405 nm laser diode) on the light scatter mode for quantification and scatter distribution.
In an initial exploration of the transplant-exosome strategy in people, the team examined stored blood plasma samples from five recipients of transplanted islet cells in a clinical trial, and was able to detect donor exosomes in these samples following the transplants. They also found some preliminary evidence that their falling-exosome measure could be useful in predicting transplant rejection in people. For one patient who experienced a rejection of the transplanted islet cells, a steep drop in the level of donor exosomes was detectable in a blood sample taken six and a half months before the transplanted cells stopped working and the patient developed clinical signs of diabetes.
The scientists showed that they could isolate and detect donor-tissue exosomes in a different type of transplant: kidney transplant, currently the most common type of organ transplant. In this case, the team found that they could isolate and quantify donor-kidney exosomes not just in blood but also in urine, thus potentially enabling urine tests which are even less invasive than blood tests. Ali Naji, MD, PhD, a Professor of Surgery and senior author of the study said, “I believe that analyses of exosomes from transplanted organs will ultimately provide a very powerful and unprecedented ability to understand the conditional state of the organ as a whole.” The study was published on March 20, 2017, in the Journal of Clinical Investigation.
Latest Molecular Diagnostics News
- Novel Algorithm Improves Detection of B-ALL Gene Fusions
- Rapid Multiplex PCR Test Detects 11 Gastrointestinal Pathogens from Single Sample
- Sensitive Protein Marker Aids Diagnosis of Small Cell Prostate Cancer
- Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC
- Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
- Blood-Based “Ageing Clock” Helps Predict Dementia Risk and Earlier Onset
- Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
- Blood Test Refines Biopsy Decisions in Prostate Cancer
- Digital Aging Twin Quantifies Biological Aging Across Multiple Organ Systems
- Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
- Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
- Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
- Patented Isothermal Amplification Chemistry Advances Decentralized Testing
- Direct-to-Patient Genetic Testing Identifies Hereditary Cancer Risk in Survivors
- Stool DNA Analysis Tracks Disease Activity in IBD
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more








